Serious adverse events (Figure 6)
Serious adverse events were evaluated based on the following three outcomes: the number of patients experiencing a serious adverse event, the number of serious adverse events related to the trial regimen, and the number of serious adverse events leading to trial discontinuation. Six out of 7 studies [5,10,13-17] reported the aforementioned outcomes, and the pooled analysis revealed that the number of patients experiencing serious adverse events was marginally lower in the Finerenone group compared to the placebo group (RR = 0.95 [0.92, 0.97] p < 0.0001; I2 = 0%). Similarly, the risk of treatment discontinuation due to serious adverse events was marginally lower in the Finerenone group compared to the placebo group (RR = 0.94 [0.83, 1.07] p= 0.38; I2= 0%), whereas risk of serious adverse events related to trial regimen was higher in patients treated with Finerenone (RR = 1.36 [1.13, 1.64] p = 0.001; I2= 0%).